



Hua Medicine

2022 Interim Results Announcement Webinar Invitation

Dear investors and analysts, Hua Medicine (2552.HK) cordially invites you or your representative to attend the online webinar in relations to the Company's 2022 interim results, which will be held 9:00 AM GMT+8, 26 August 2022 (Friday).

During the webinar, management will provide a review of the Company's interim financial results in 2022, business updates, as well as address plans for the future.

Details of the webinar are as follows:

Language:	English
Date:	26 August 2022 (Friday)
Time:	Login starts: 8:45AM GMT+8 Meeting starts: 9:00AM GMT+8
Duration:	Approx. 45 mins (including Q&A session)
Management:	Dr. Li Chen, CEO, Founder, and Chief Scientific Officer Mr. George Lin, Chief Financial Officer and Executive Vice President
RSVP:	Registration Link: https://icaasia.zoom.us/webinar/register/WN_1qJJAQo0QCaD19R2NEyIZQ (Please register via the above link no later than 25 August 2022) 1. Registration is invite-only and is subject to company approval. 2. Upon successful registration, a personalized meeting link will be sent to the registered email. Please use the link to access the meeting.
Q&A:	If you have any questions, please send them to huamedicine@icaasia.com before 25 August 2022 (Thursday). Company management will address the received questions during the Q&A session. Other questions could also be raised during the Q&A session subject to the meeting time.

**If you are intended to attend the Chinese session (10:00AM GMT+8, 26 August), please send an email to huamedicine@icaasia.com for registration. Meeting details will be provided upon confirmation.*

About Hua Medicine

Hua Medicine is an innovative drug development company found in China focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. Targeting on glucose sensor glucokinase, dorzagliatin, as its cornerstone product, restores glucose sensitivity in T2D patients and has completed SEED and DAWN registration trials, with its NDA accepted by the National Medical Products Administration (NMPA) in China. This first-in-class glucokinase activator has demonstrated its potential of achieving diabetes remission to help millions of diabetic patients around the world.